Summary: This paper describes the new enzyme immunoassays for the measurement of oc-fetoprotein (AFP), carcinoembryonic antigen (CEA) and prostate-specific antigen (PSA) in serum and heparinised plasma as developed for the fully automated Serono SRI™ analyzer. Each assay incorporates two monoclonal antibodies in an immunoenzymetric sandwich format using alkaline phosphatase as the label and magnetic solid phase separation. All processing steps are performed by the SRI.
Introduction
oc-Fetoprotein (AFP), carcinoembryonic antigen (CEA) and prostate-specific antigen (PSA) are accepted tumour markers used in the diagnosis, management and monitoring of certain cancers (1) (2) (3) . Maternal serum AFP concentrations have also been used in the detection of fetal abnormalities (4) . Various manual, semi-automated and more recently automated immunoassay methods have been described for the measurement of AFP, CEA and PSA (5-7).
Turn-around time, staff usage and assay costs can be reduced with automated immunoassays. With the continued growing use of immunoassays, the move towards automated systems is becoming more desirable. It is with this in mind that we present a summary of the tumour marker assays for the measurement of AFP, CEA and PSA in serum and heparinised plasma on the fully automated SRI analyzer.
Materials and Methods
Assay specific reagents were provided by Serono Diagnostics S. A., Coinsins, Switzerland.
Patient samples obtained from UK hospital laboratories were stored frozen at -20 °C until they were assayed.
Cattini el aJ.: Measurement of AFP, CEA and PSA on the automated SRI™ analyzer Commercial control sera (Lyphochek ECS Controls 1, 2 and 3 Lot No. 90000) were purchased from Biorad Laboratories, Herts, UK.
Other immunoassays were obtained from: Abbott Diagnostics Division, Chicago, Illinois, USA; Hybritech Europe S. A., Liege, Belgium.
Assay procedures
All AFP, CEA and PSA determinations were performed on the SRI analyzer. For each of the assays two monoclonal antibodies are used in an immunoenzymetric assay system which incorporates magnetic solid phase separation. All incubation times and reagent volumes are determined by an assay specific software protocol.
The principle of the procedure for all of the assays is identical. Fixed amounts of fluorescein-labelled anti-(AFP, CEA or PSA) mouse monoclonal antibody and a calf intestinal alkaline phosphatase-labelled anti-(AFP, CEA or PSA) monoclonal antibody are added to sample, standard or control. The reactants are incubated at 37 °C. During the incubation the fluorescein-labelled anti-(AFP, CEA or PSA) and the alkaline phosphataselabelled anti-(AFP, CEA or PSA) monoclonal antibodies bind to discrete sites on the AFP, CEA or PSA molecule forming a sandwich. At the end of the incubation period anti-fluorescein coupled to a magnetic solid phase is added in excess. This rapidly and specifically binds to the AFP, CEA or PSA-antibody complexes and is sedimented in a magnetic field. After aspirating the liquid phase and washing the solid phase, a solution of the enzyme substrate (phenolphthalein monophosphate) is added and the mixture incubated at 37 °C. After incubation the enzyme reaction is stopped by the addition of an alkaline buffer (pH 10.6) and the intensity of the colour developed is measured photometrically. The intensity of the colour developed is directly proportional, within the working range of the assay, to the concentration of AFP, CEA or PSA in the sample. The concentration of AFP, CEA or PSA in a patient sample or control is then determined by interpolation from a stored standard curve.
Detection limit
The detection limit for each assay was defined as the concentration of analyte equivalent to the mean absorbance of the zero standard plus two standard deviations based on twenty replicates of the zero analyte standard.
Precision
Within-assay precision was determined by replication (n = 20) of three concentrations of control sera. To assess between-assay precision, three concentrations of control sera were assayed in duplicate on at least forty occasions over a period of five weeks using two lots of reagents and at least five SRI analyzers.
Recovery
The recovery of each assay was determined by adding known quantities of AFP, CEA or PSA to serum samples containing low endogenous analyte concentrations, assaying the serum samples and determining the recovery of the amount added. International reference preparations were used to prepare spikes for AFP (IRP 72/225) and CEA (IRP 73/601). Since there is no available reference preparation for PSA, the source of added PSA was PSA-containing serum.
Dilution
Five serum samples containing elevated concentrations of AFP, CEA or PSA within the respective assay ranges, were diluted 1 in 2, 1 in 4, 1 in 8, 1 in 16 und l in 32 in the appropriate assay diluent. The samples and their dilutions were then assayed to determine linearity on dilution. Results were interpreted by linear regression analysis of observed concentrations versus expected concentration.
Interference
Assay interference was assessed by measuring the apparent response of each assay to various concentrations of potential interfering substances spiked into normal human serum. The basal serum and the spiked serum samples were then assayed.
Hook effect (8) Very high antigen concentrations will produce anomalously low results in simultaneous sandwich immunoassays (the "hook effect"). The hook effect for each assay was evaluated by analysing samples with elevated concentrations prepared by spiking patients' sera with AFP, CEA or PSA respectively.
Correlation with other immunoassays
The SRI AFP, CEA and PSA assays were compared with the following immunoassays:
Abbott Diagnostics, IMx™ (AFP and CEA)
The competitor's assay values were plotted on the y-axis.
Expected values
For each assay, values were determined in a population of apparently healthy blood donors, from patients with carcinomas (treated and untreated), patients with non-malignant disease and, for AFP only, from pregnant women (gestational weeks 15 to 19 inclusive). Table 1 summarises each of the assay protocols for AFP, CEA and PSA. After manual pipetting of sample, all further reagent addition and incubation steps are performed by the SRI. The time to first result for the assays is approximately one hour and thereafter two results are obtained every two minutes. Results are interpolated automatically from a previously run stored standard curve (stable for up to three months).
Results

Assay protocols
"Detection limit
The detection limits determined on at least four occasions for AFP, CEA and PSA were typically 0.24 g/l, 1.0 g/l and 0.1 g/l respectively. 
Dilution
The linearity on dilution was determined by multiple dilution of five samples for each assay. The observed concentration was plotted against the expected conTab. 4. Linearity on dilution. 
Hook effect
No high-dose hook effect was observed for the AFP, CEA and PSA assays with concentrations up to 12100 μg/l J 26667 μg/l and 30000 μg/l respectively. Includes treated and untreated patients. 
Discussion
The SRI tumour marker assays fulfil the following analytical criteria:
(i) suitable ranges and detection limits for clinical applications.
(ii) robust and reproducible: the precision of the assays is good with the CV for within-assay precision less than 8% and between-assay precision less than 12%.
(iii) excellent recovery and linearity on dilution.
(iv) no interference from potential interfering substances.
(v) the hook capacity for each assay is well in excess of concentrations encountered usually with clinical patient samples.
•» (vi) correlation data shows good agreement with other existing immunoassays. The spread of results obtained for the SRI AFP, CEA and PSA assays in healthy blood donors and various types of malignant and non-malignant diseases are distributed as would be expected for clinically valid assays. In pregnancy, the expected relationship between gestational week and maternal serum median AFP values was confirmed. In cases of anencephaly SRI AFP maternal serum concentrations were markedly higher than in healthy pregnancies. This has been reported in the literature (12) . Smokers gave higher CEA values than non-smokers, which concurs with published results (13) . In addition, male blood donors gave higher CEA values than female blood donors and blood donors > 45 years gave higher CEA values than blood donors < 45 years. The difference with increasing age has been described in the scientific literature (14) . The median PSA value for male blood donors increased with age and female blood donors gave a lower median PSA value than all male blood donors. The median female PSA value of < 0.1 μ §^1, a reflection of the clinical detection limit of the assay, compared well with the lowest detectable value calculated by the standard method (i. e. precision of 20 replicates of the zero standard). In addition the SRI PSA concentrations from prostatectomised men were generally very low and compared well with results obtained using the Hybritech Tandem-R PSA assay (15).
In conclusion, these results demonstrate the ability of the SRI AFP, CEA and PSA assays to contribute towards accurate clinical diagnosis and monitoring of certain cancers and, for AFP, of fetal abnormalities. In addition, the SRI offers the advantages of nonisotopic, walk-to walk-away automation, easy handling, short turn around times and random access and batch modes of operation using stored standard curve calibration.
